Altitude Life Science Ventures Fund II L.P. 13D and 13G filings for eFFECTOR Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-05 4:15 pm Purchase |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Altitude Life Science Ventures Fund II L.P. | 2,826,350 4.400% |
2,713,296 (+2400.00%) |
Filing |
| 2023-03-07 5:25 pm Purchase |
2021-08-25 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Altitude Life Science Ventures Fund II L.P. | 113,054 6.700% |
113,054 (New Position) |
Filing |